21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Gold buy
Period: 31.01.2026 Expectation: 150 pips
Buying gold on dips with $4,500 target
30 December 2025 229
Period: 06.01.2026 Expectation: 2900 pips
Tesla stock selloff on forecasts of declining deliveries and earnings
30 December 2025 104
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 16.01.2026 Expectation: 1000 pips
AUDUSD is consolidating ahead of renewed upside
30 December 2025 97
Period: 06.01.2026 Expectation: 3125 pips
Selling BTCUSD due to lack of momentum after December consolidation
30 December 2025 58
Period: 15.01.2026 Expectation: 100 pips
Investing in SPX from $6,870
30 December 2025 70
Period: 09.01.2026 Expectation: 7500 pips
Silver rally stalls as prices push past $80
29 December 2025 114
Go to forecasts